Evidence map›Paper›PMID 22217738›Full record

ReviewThe Journal of investigative dermatology2012

Applications of nanotechnology in dermatology.

Lisa A DeLouise

Abstract readReview
In one paragraph

Review in The Journal of investigative dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Small molecules targeting endocytic uptake and recycling pathways.Frontiers in cell and developmental biology · 2023
    Review
  9. Veterinary nanomedicine: Pros and cons.Veterinary medicine and science · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Lipid-Based Nanosystems as a Tool to Overcome Skin Barrier.International journal of molecular sciences · 2021
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lisa A DeLouiseDepartment of Biomedical Engineering, University of Rochester, Rochester, New York 14642, USA. Lisa_DeLouise@urmc.rochester.edu

Funding

Quantifying Risk Factors for Nanoparticle Contact with UVB Exposed SkinR01ES021492 · NIEHS · UNIVERSITY OF ROCHESTER · PI DELOUISE, LISA A · 2012 to 2022
$3.5M
Reagents to Enhance Detection of Raw and Biologically Transformed NanomaterialsR21OH009970 · OH · UNIVERSITY OF ROCHESTER · PI DELOUISE, LISA A · 2011 to 2012
$403k
NIEHS NIH HHS R01 ES021492NIOSH CDC HHS R21OH009970
6 · The paper itself

Abstract

What are nanoparticles and why are they important in dermatology? These questions are addressed by highlighting recent developments in the nanotechnology field that have increased the potential for intentional and unintentional nanoparticle skin exposure. The role of environmental factors in the interaction of nanoparticles with skin and the potential mechanisms by which nanoparticles may influence skin response to environmental factors are discussed. Trends emerging from recent literature suggest that the positive benefit of engineered nanoparticles for use in cosmetics and as tools for understanding skin biology and curing skin disease outweigh potential toxicity concerns. Discoveries reported in this journal are highlighted. This review begins with a general introduction to the field of nanotechnology and nanomedicine. This is followed by a discussion of the current state of understanding of nanoparticle skin penetration and their use in three therapeutic applications. Challenges that must be overcome to derive clinical benefit from the application of nanotechnology to skin are discussed last, providing perspective on the significant opportunity that exists for future studies in investigative dermatology.

Indexed as

Cosmetic TechniquesDermatologyHumansNanotechnologySkin Diseases

Identifiers

PMID22217738
PMCPMC4066738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.